Human carotid atherosclerotic plaque increases oxidative state of macrophages and low-density lipoproteins, whereas paraoxonase 1 (PON1) decreases such atherogenic effects

被引:50
作者
Tavori, Hagai [1 ,2 ,3 ]
Aviram, Michael [3 ]
Khatib, Soliman [1 ,2 ]
Musa, Ramadan [1 ,2 ]
Nitecki, Samy [4 ]
Hoffman, Aaron [4 ]
Vaya, Jacob [1 ,2 ]
机构
[1] MIGAL Galilee Technol Ctr, Lab Nat Med Cpds, IL-11016 Kiryat Shmona, Israel
[2] Tel Hai Coll, Upper Galilee, Israel
[3] Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, Fac Med, Lipid Res Lab, IL-31096 Haifa, Israel
[4] Rambam Med Ctr, Dept Vasc Surg & Transplantat, IL-31096 Haifa, Israel
基金
以色列科学基金会;
关键词
Atherosclerosis; Oxidative Stress; Paraoxonase; Plaque; CHOLESTEROL EFFLUX; SERUM PARAOXONASES; LACTONASE ACTIVITY; LIPID PEROXIDES; HDL BINDING; LESIONS; OXYSTEROLS; STRESS; MICE; MARKER;
D O I
10.1016/j.freeradbiomed.2008.11.019
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human atherosclerotic plaque contains a variety of oxidized lipids, which can facilitate further oxidation. Paraoxonase 1 (PON1) is a high-density lipoprotein (HDL)-associated esterase (lipolactonase), exhibiting antiatherogenic properties. The aims of the present study were to examine the oxidizing potency of the human carotid plaque lipid extract (LE), and the antiatherogenic role of PON1 on LE oxidation competence. Human carotid plaques were extracted by organic solvent, and the extract was incubated with lipoprotein particles, with macrophages, or with probes sensitive to oxidative stress, with or without preincubation with PON1, followed by oxidative-stress assessment. Our findings imply that the LE oxidized LDL, macrophages, and exogenous probes and decreases HDL-mediated cholesterol efflux from macrophages, in a dose-dependent manner. Incubation of PON1 with LE significantly affects LE composition, reduces LE atherogenic properties, and decreases the extract's total peroxide concentration by 44%, macrophage oxidation by 25%, and probe oxidation by tip to 52%. We conclude that these results expand our understanding of how the plaque itself accelerates atherogenesis and provides an important mechanism for attenuation of atherosclerosis development by the antioxidant action of PON1 on the atherosclerotic plaque. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:607 / 615
页数:9
相关论文
共 64 条
[1]   Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization [J].
Aharoni, A ;
Gaidukov, L ;
Yagur, S ;
Toker, L ;
Silman, I ;
Tawfik, DS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (02) :482-487
[2]   OXYSTEROL-INDUCED APOPTOSIS IN HUMAN MONOCYTIC CELL-LINES [J].
AUPEIX, K ;
WELTIN, D ;
MEJIA, JE ;
CHRIST, M ;
MARCHAL, J ;
FREYSSINET, JM ;
BISCHOFF, P .
IMMUNOBIOLOGY, 1995, 194 (4-5) :415-428
[3]   PLASMA-LIPOPROTEIN SEPARATION BY DISCONTINUOUS DENSITY GRADIENT ULTRA-CENTRIFUGATION IN HYPERLIPOPROTEINEMIC PATIENTS [J].
AVIRAM, M .
BIOCHEMICAL MEDICINE, 1983, 30 (01) :111-118
[4]   LESIONED LOW-DENSITY-LIPOPROTEIN IN ATHEROSCLEROTIC APOLIPOPROTEIN E-DEFICIENT TRANSGENIC MICE AND IN HUMANS IS OXIDIZED AND AGGREGATED [J].
AVIRAM, M ;
MAOR, I ;
KEIDAR, S ;
HAYEK, T ;
OIKNINE, J ;
BAREL, Y ;
ADLER, Z ;
KERTZMAN, V ;
MILO, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 216 (02) :501-513
[5]   Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions - PON1 esterase and peroxidase-like activities [J].
Aviram, M ;
Hardak, E ;
Vaya, J ;
Mahmood, S ;
Milo, S ;
Hoffman, A ;
Billicke, S ;
Draganov, D ;
Rosenblat, M .
CIRCULATION, 2000, 101 (21) :2510-2517
[6]   Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions - A possible peroxidative role for paraoxonase [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS ;
Primo-Parmo, SL ;
La Du, BN .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (08) :1581-1590
[7]  
Aviram M, 2000, FREE RADICAL RES, V33, pS85
[8]  
AVIRAM M, 1999, CURR INT CARDIOL REP, V1, P66
[9]  
Aviram M., Handb Exp Pharmacol, P263
[10]  
Badimon J.J., 1993, CIRCULATION, V87, P113